Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,071.63 +1.08 (+0.02%) Dow
38,460.92 -42.77 (-0.11%) Nasdaq
15,712.75 +16.11 (+0.10%) Bitcoin USD
64,093.73 -2,167.73 (-3.27%) CMC Crypto 200
1,385.11 -38.99 (-2.74%)
Aditxt, Inc. (ADTX)
After hours:
| Previous close | 2.2700 |
| Open | 2.4100 |
| Bid | 2.2300 x 100 |
| Ask | 2.4400 x 100 |
| Day's range | 2.2700 - 2.4100 |
| 52-week range | 2.1400 - 68.0800 |
| Volume | |
| Avg. volume | 375,882 |
| Market cap | 3.947M |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -108.1500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
MOUNTAIN VIEW, Calif., April 02, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("Arrangement Agreement") to acquire Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Under the Arrangement Agree
PR NewswireEvofem Reports $18.2 million of Phexxi Net Product Sales in 2023
The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include:
- PR Newswire
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity.2 These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more
